Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 10, 2022
Daily News
November 10, 2022
- Expert Panel Discussion Summary Reported to Chuikyo; Payer Rep Sees No Need for Inflation Response in Off Year
November 10, 2022
- Polivy Likely to Escape CEA-Based Price Tweaks
November 10, 2022
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
- JPMA Lauds Govt’s Proposed Extra Budget for Enhanced Startup Support
November 10, 2022
- Extra Budget to Cover Enough COVID Vaccine Purchases until Next Winter
November 10, 2022
- METI Looks to Bolster Pharma Startup Ecosystem with 6-Fold Hike in Extra Budget
November 10, 2022
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- My Linh Kha to Become Interim Chief of Amgen Japan
November 10, 2022
- Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
November 10, 2022
- Industry Reiterates Call for Careful Discussions on Off-Year Revision: LDP Confab
November 10, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…